Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.

Marina Chiara Garassino,Alain Jonathan Gelibter, Francesco Grossi,Rita Chiari,Hector Soto Parra,Stefano Cascinu,Francesco Cognetti,Daniele Turci,Livio Blasi,Carmelo Bengala,Enrico Mini,Editta Baldini,Silvia Quadrini,Giovanni Luca Ceresoli,Paola Antonelli,Enrico Vasile,Carmine Pinto,Gianpiero Fasola,Domenico Galetta,Marianna Macerelli,Diana Giannarelli, Giuseppe Lo Russo, Filippo de Marinis

Journal of Thoracic Oncology（2018）

引用 77|浏览94

暂无评分

摘要

Italian EAP data in nonsq-NSCLC populations suggest that subgroups of patients could benefit differently from nivolumab according to EGFR mutational status and smoking habits. These results warrant further investigation.

查看译文

关键词

Nonsquamous non–small cell lung cancer,Expanded access program,nivolumab,EGFR positive,Never-smokers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要